Structured around the objectives of improving (1) the quality of life and life expectancy of metastatic cancer patients and (2) reducing healthcare cost by preventing and treating side effects associated with chemotherapy, Sanarentero, LLC is an early-stage start-up developing therapies for drug-induced side effect management with special focus on cancer chemotherapy. In collaboration with College of Pharmacy, University of Houston, the firm has generated key preliminary data in rodents to show the efficacy of the product. In the pipeline, Sanarentero also has a product addessing the treatment and prevention of chemotherapy-induced diarrhea.
